News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN)'s Chemo Drug Caprelsa Works Against Thyroid Cancer in Phase II Trial


8/15/2012 8:09:28 AM

A new study shows that the chemotherapy drug vandetanib (Caprelsa) may extend life a bit for some thyroid cancer patients. The results of phase 2 trials showed that patients taking the drug lived for 11 months without the cancer progressing, compared with six months for those receiving a placebo. "This study is confirmation that vandetanib is effective in advanced thyroid cancer patients, not only in terms of overall response, but also in terms of progression-free survival," said lead researcher Dr. Martin Schlumberger, of the Institute Gustave Roussy in Villejuif, France. "Vandetanib should be used as first-line treatment in patients with progressive, untreatable thyroid cancer."

Read at HealthDay
Read at MedicalXpress
Read at News Release
Read at NetDoctor (UK)

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES